| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5543152 | ACROTECH | Sphingosomes for enhanced drug delivery |
Jun, 2014
(9 years ago) | |
| US5814335 | ACROTECH | Sphingosomes for enhanced drug delivery |
Jun, 2014
(9 years ago) | |
| US5741516 | ACROTECH | Sphingosomes for enhanced drug delivery |
Jun, 2014
(9 years ago) | |
| US6723338 | ACROTECH | Compositions and methods for treating lymphoma |
Mar, 2020
(4 years ago) | |
| US7887836 | ACROTECH | Compositions and methods for treating lymphoma |
Mar, 2020
(4 years ago) | |
| US7247316 | ACROTECH | Compositions and methods for treating lymphoma |
Sep, 2020
(3 years ago) | |
Marqibo Kit is owned by Acrotech.
Marqibo Kit contains Vincristine Sulfate.
Marqibo Kit has a total of 6 drug patents out of which 6 drug patents have expired.
Expired drug patents of Marqibo Kit are:
- US5543152
- US5814335
- US5741516
- US6723338
- US7887836
- US7247316
Marqibo Kit was authorised for market use on 09 August, 2012.
Marqibo Kit is available in injectable, liposomal;intravenous dosage forms.
Marqibo Kit can be used as treatment of adult patients with philadelphia chromosome-negative(ph-) acute lymphoblastic leukemia (all) in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies.
The generics of Marqibo Kit are possible to be released after 25 September, 2020.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-28) | Aug 09, 2019 |
| New Product(NP) | Aug 09, 2015 |
| Orphan Drug Exclusivity(ODE) | Aug 09, 2019 |
Drugs and Companies using VINCRISTINE SULFATE ingredient
Market Authorisation Date: 09 August, 2012
Treatment: Treatment of adult patients with philadelphia chromosome-negative(ph-) acute lymphoblastic leukemia (all) in second or greater relapse or whose disease has progressed following two or more anti-leukem...
Dosage: INJECTABLE, LIPOSOMAL;INTRAVENOUS
MARQIBO KIT family patents
